Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen

D. J. Bentrem, R. C. Dardes, H. Liu, J. Macgregor-Schafer, J. W. Zapf, V. C. Jordan*

*Corresponding author for this work

Research output: Contribution to journalArticle

73 Scopus citations

Abstract

Tamoxifen is the endocrine treatment of choice for all stages of estrogen receptor (ER)-positive breast cancer, and it is the first drug approved to reduce the incidence of breast cancer in high-risk women. Unfortunately, tamoxifen also possesses some estrogen-like effects in the uterus that cause a modest increase in the risk of endometrial cancer. GW5638 is a tamoxifen derivative with a novel carboxylic acid side chain with no uterotropic activity in the rat (Willson et al., J Med Chem, 1994, 37:1550-1552). We have compared and contrasted the actions of 4-hydroxytamoxifen (4-OHT, the active metabolite of tamoxifen) with GW7604 [the presumed metabolite of GW5638 in breast (MCF-7) and endometrial (ECC-1) cell lines in vitro]. GW7604 did not cause the growth of ECC-1 cells at any concentration (10-11-10-6 M), but 4-OHT was weakly estrogen-like at low concentrations (10-11-10-10 M). Compounds (10-7 M) blocked the growth promoting action of estradiol (10-10 M) in both ECC-1 and MCF-7 cells. Western blotting was used to show that GW7604 and raloxifene did not affect ER levels significantly, compared with controls, in MCF-7 cells; whereas the pure antiestrogen ICI182,780 decreased ER levels (P < 0.05). An assay system was used that can classify compounds into tamoxifen-like, raloxifene-like, or pure antiestrogens. The assay depends on the activation of the transforming growth factor α (TGFα) gene in situ by wild-type or D351Y mutant ER stably transfected into MDA-MB-231 cells (MacGregor-Schafer et al., Cancer Res, 1999, 59: 4308-4313). GW7604 inhibited both estradiol (10-9 M) and 4-OHT (10-8, 10-7 M) induction of TGFα in a concentration related manner (10-9-10-6 M). GW7604 and raloxifene stimulated TGFα with the D351YER. In contrast, ICI182,780 (10-6 M) did not initiate TGFα and blocked the induction of TGFα with GW7604, raloxifene, and 4-OHT in D351Y-transfected cells. Using computer-assisted molecular models of ER complexes, we found that the antiestrogenic side chain of 4-OHT weakly interacted with the surface amino acid 351 (aspartate), but the carboxylic acid of GW7604 caused a strong repulsion of aspartate 351. We propose that GW7604 is less estrogen-like than 4-OHT, because it disrupts the surface charge around aa351 required for coactivator docking in the 4-OHT:ER complex. This charge is restored in the D351Y ER, thus converting GW7604 from an antiestrogen to an estrogen-like molecule.

Original languageEnglish (US)
Pages (from-to)838-846
Number of pages9
JournalEndocrinology
Volume142
Issue number2
DOIs
StatePublished - 2001

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen'. Together they form a unique fingerprint.

Cite this